Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Products>This Product

Assay Development, small molecule HTS and Hit To Lead services

Product Description

Hybrigenics offers full and customized drug discovery services to identify small molecules modulating protein interactions and to optimize them.

We have a strong expertise in protein-protein interactions small molecule screening with more than 40 assays developed. We also offer assays targeting enzymatic activities (eg: proteases, kinases).
You can choose to screen our generalist library of 100,000 diverse compounds (or a subset of it) or our natural compound library composed of 2,000 pure compounds and 40,000 enriched plant extracts. The screening steps comprise the identification, confirmation and analytical validation of primary hits.

Otherwise, we can also screen your own library and even transfer the assay to you.

Several hit to lead services are also available:
- Analoging
- Compound Evaluation
- Secondary Assay Development and Screening
- Structure-Analysis Relationship (SAR) Analysis

Our offer is flexible:  we take care of your project at any step from assay development to hit characterization.

For more details, please go to:

Product Assay Development, small molecule HTS and Hit To Lead services
Company Hybrigenics Services SAS
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Hybrigenics Services SAS
3-5 Impasse Reille 75014 Paris France

Tel: +33 (0)1 58 10 38 29
Fax: +33 (0)1 58 10 38 48

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos